Melanie S. Hulshoff

Robert Koch Str. 40
Goettingen, NI 37075, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Vedolizumab treatment outcomes in early versus late Crohn's disease - Authors' reply.

Vedolizumab treatment outcomes in early versus late Crohn's disease - Authors' reply.

Journal: The lancet. Gastroenterology & hepatology

Published: January 19, 2026

Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.

Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.

Journal: Cardiovascular research

Published: July 05, 2025

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.

Journal: The lancet. Gastroenterology & hepatology

Published: May 15, 2025

Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.

Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.

Journal: The lancet. Gastroenterology & hepatology

Published: August 28, 2024

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: July 17, 2024

Cost-effectiveness and cost-utility of optimized mercaptopurine treatment versus placebo in ulcerative colitis patients: The randomized controlled OPTIC trial.

Cost-effectiveness and cost-utility of optimized mercaptopurine treatment versus placebo in ulcerative colitis patients: The randomized controlled OPTIC trial.

Journal: United European gastroenterology journal

Published: May 09, 2024

Loss of tet methyl cytosine dioxygenase 3 (TET3) enhances cardiac fibrosis via modulating the DNA damage repair response.

Loss of tet methyl cytosine dioxygenase 3 (TET3) enhances cardiac fibrosis via modulating the DNA damage repair response.

Journal: Clinical epigenetics

Published: March 12, 2024

Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.

Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.

Journal: Journal of Crohn's & colitis

Published: November 07, 2023

Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?

Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?

Journal: Expert opinion on biological therapy

Published: April 03, 2023

miR-132-3p and KLF7 as novel regulators of aortic stiffening-associated EndMT in type 2 diabetes mellitus.

miR-132-3p and KLF7 as novel regulators of aortic stiffening-associated EndMT in type 2 diabetes mellitus.

Journal: Diabetology & metabolic syndrome

Published: November 23, 2022

Emerging therapies for ulcerative colitis.

Emerging therapies for ulcerative colitis.

Journal: Expert review of clinical immunology

Published: April 28, 2022

CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications.

CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications.

Journal: International journal of molecular sciences

Published: April 02, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026